James Rae, PhD

 James M. Rae
Associate Professor
Email:
[email protected]
Available to mentor
James Rae, PhD
James M. Rae
Associate Professor
  • Center Memberships
  • Recent Publications

  • Manage Your Profile

    • Center Memberships
    • Center Member
      Rogel Cancer Center

    Recent Publications

     See All Publications
    • Journal Article
      Unlocking 30-Year-Old Archival Formalin-Fixed Paraffin-Embedded Breast Cancer Specimens (SWOG S8897): An Analytical Feasibility Study.
      Johann DJ, Hicks J, Albain KS, Barlow WE, Godwin AK, Hayes DF, Hutchins LF, Killian JK, Peterson EA, Pina-Oviedo S, Pusztai L, Rae JM, Sharma P, Shin IJ, Thompson AM. JCO Precis Oncol, 2026 Oct; 10 (10): e2600152 DOI:10.1200/PO-26-00152
      PMID: 42842842
    • Presentation
      Changes in Oncology Translational Medicine Research
      Rae J. 2026 Jul 7;
    • Journal Article
      First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.
      Nappi L, Colby S, Hamilton RW, Harzstark A, Adra N, Daneshmand S, Ryan CW, Eggener SE, Fung C, Johnson R, Lerner SP, Arnold KB, Arun B, Rae JM, Blanke CD, LeBlanc M, Parulekar WR, Einhorn LH, Kollmannsberger CK, Nichols CR, Investigators OBOTSSCG1. Journal of Clinical Oncology, 2026 Jun 5; 44 (17_suppl): lba5003 - lba5003. DOI:10.1200/jco.2026.44.17_suppl.lba5003
    • Journal Article
      External validation of a MMAI model for prognosis and chemotherapy benefit prediction in postmenopausal, node-positive, hormone receptor–positive breast cancer patients: Analysis of SWOG S8814.
      Speers CW, Piehler A, Meisner A, Zhang J, Barlow WE, Zwerink W, Pusztai L, Sharma P, Chao CY, Thompson AM, Godwin AK, Albain KS, Griffin JR, Rae JM. Journal of Clinical Oncology, 2026 May 29; 44 (16_suppl): 107 - 107. DOI:10.1200/jco.2026.44.16_suppl.107
    • Proceeding / Abstract / Poster
      Abstract 6604: Aurora kinase B inhibition enhances radiation response and activates type 1 interferon signaling in triple-negative breast cancer.
      Endraws MA, Jungles KM, Bishop C, Wilson C, Rana PS, Hauk B, Diedrich C, Markovic V, Hochmuth E, McBean BN, Liu M, Pierce L, Rae JM, Speers CW. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 6604 - 6604. DOI:10.1158/1538-7445.am2026-6604
    • Proceeding / Abstract / Poster
      Abstract 5290: Investigating the intrinsic epigenetic dependencies of estrogen receptor positive and ESR1 mutant breast cancer
      Coleski A, Young E, Das S, Cao X, VanAken S, Su F, Cao Y, Wang R, Rae JM, Parolia A, Qiao Y, Xiao L, Chinnaiyan AM. Cancer Research, 2026 Apr 17; 86 (7_Supplement): 5290 - 5290. DOI:10.1158/1538-7445.am2026-5290
    • Journal Article
      Abstract PS2-07-22: Serial, multi-omic, multi-analyte, liquid biopsy monitoring of metastatic lobular breast cancer to detect clinically-relevant heterogeneity and evolution
      Cani AK, Dolce EM, Darga EP, Hu K, Liu C, Robinson D, Wu Y, Paoletti C, Luker GD, Tomlins SA, Udager AM, Henderson NC, Thomas DG, Rae JM, Arul CM, Cobain EF, Hayes DF. Clinical Cancer Research, 2026 Feb 23; 32 (4_Supplement): ps2-07-22-ps2-07-22 DOI:10.1158/1557-3265.sabcs25-ps2-07-22
    • Presentation
      Targeting CBP/p300 in Estrogen Receptor-Positive Breast Cancer
      Rae J. 2026 Jul 7;